AbbVie (ABBV) Tops Q4 EPS by 3c, Confirms Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
AbbVie (ABBV) PT Trimmed at Jefferies But Sees Excellent Entry Point
February 3, 2015 8:41 AM ESTJefferies analyst Jeffrey Holford reiterated a Buy rating on Abbvie (NYSE: ABBV) following Q4 results but lowered his price target to $80.00 (from $82.00). The firm said recent weakness creates an excellent entry point.
Holford commented, "We view ABBV's 2015 HCV guidance as conservative, which is... More
